Brainsway (BWAY) Competitors $11.76 -0.07 (-0.59%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$11.78 +0.02 (+0.17%) As of 08/8/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BWAY vs. IRMD, KMTS, SIBN, BBNX, EMBC, AXGN, ZIMV, BVS, CBLL, and AVNSShould you be buying Brainsway stock or one of its competitors? The main competitors of Brainsway include iRadimed (IRMD), Kestra Medical Technologies (KMTS), SiBone (SIBN), Beta Bionics (BBNX), Embecta (EMBC), AxoGen (AXGN), ZimVie (ZIMV), Bioventus (BVS), CeriBell (CBLL), and AVANOS MEDICAL (AVNS). These companies are all part of the "medical equipment" industry. Brainsway vs. Its Competitors iRadimed Kestra Medical Technologies SiBone Beta Bionics Embecta AxoGen ZimVie Bioventus CeriBell AVANOS MEDICAL Brainsway (NASDAQ:BWAY) and iRadimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings. Does the media refer more to BWAY or IRMD? In the previous week, iRadimed had 3 more articles in the media than Brainsway. MarketBeat recorded 5 mentions for iRadimed and 2 mentions for Brainsway. iRadimed's average media sentiment score of 0.70 beat Brainsway's score of 0.36 indicating that iRadimed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral iRadimed 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in BWAY or IRMD? 30.1% of Brainsway shares are held by institutional investors. Comparatively, 92.3% of iRadimed shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 36.8% of iRadimed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable valuation & earnings, BWAY or IRMD? iRadimed has higher revenue and earnings than Brainsway. iRadimed is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBrainsway$41.02M5.42$2.92M$0.2058.80iRadimed$73.24M12.15$19.23M$1.6243.17 Is BWAY or IRMD more profitable? iRadimed has a net margin of 26.61% compared to Brainsway's net margin of 9.01%. iRadimed's return on equity of 23.30% beat Brainsway's return on equity.Company Net Margins Return on Equity Return on Assets Brainsway9.01% 7.35% 4.72% iRadimed 26.61%23.30%20.62% Which has more risk and volatility, BWAY or IRMD? Brainsway has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, iRadimed has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Do analysts recommend BWAY or IRMD? Brainsway currently has a consensus target price of $14.25, suggesting a potential upside of 21.17%. iRadimed has a consensus target price of $72.00, suggesting a potential upside of 2.96%. Given Brainsway's higher possible upside, equities analysts plainly believe Brainsway is more favorable than iRadimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainsway 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00iRadimed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryiRadimed beats Brainsway on 11 of the 15 factors compared between the two stocks. Get Brainsway News Delivered to You Automatically Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BWAY vs. The Competition Export to ExcelMetricBrainswayMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$222.26M$10.49B$5.47B$9.71BDividend YieldN/A2.00%4.59%4.12%P/E Ratio58.8020.6130.1024.70Price / Sales5.4221.69458.95100.37Price / Cash47.1623.6424.8428.01Price / Book3.553.258.525.76Net Income$2.92M$211.77M$3.27B$267.05M7 Day Performance0.34%0.16%4.63%3.13%1 Month Performance-4.47%2.56%0.94%1.27%1 Year Performance68.24%-9.81%36.49%22.83% Brainsway Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BWAYBrainsway2.8613 of 5 stars$11.76-0.6%$14.25+21.2%+68.2%$222.26M$41.02M58.80120News CoverageUpcoming EarningsAnalyst DowngradeIRMDiRadimed4.3092 of 5 stars$70.69+6.8%$72.00+1.9%+57.3%$841.36M$73.24M43.64110High Trading VolumeKMTSKestra Medical Technologies1.3491 of 5 stars$15.49+0.7%$27.33+76.5%N/A$789.75M$59.82M0.00300Positive NewsSIBNSiBone4.05 of 5 stars$17.90+2.9%$22.50+25.7%+12.2%$741.07M$167.18M-27.97350Earnings ReportAnalyst DowngradeAnalyst RevisionHigh Trading VolumeBBNXBeta BionicsN/A$16.42+0.1%$22.56+37.4%N/A$712.91M$65.12M0.00294EMBCEmbecta4.7594 of 5 stars$9.79-1.7%$19.00+94.1%-20.2%$582.09M$1.08B10.882,100Earnings ReportDividend AnnouncementGap UpAXGNAxoGen2.4966 of 5 stars$12.55-0.9%$24.50+95.2%+26.1%$577.04M$187.34M-83.66450Analyst UpgradeAnalyst RevisionZIMVZimVie0.7114 of 5 stars$18.77+0.1%$17.75-5.4%+4.0%$529.05M$449.75M-26.811,770BVSBioventus2.8831 of 5 stars$6.32+2.3%$13.75+117.6%-8.8%$519.15M$567.70M-10.361,200Analyst RevisionCBLLCeriBell2.4445 of 5 stars$15.23+7.7%$32.14+111.0%N/A$511.06M$65.44M0.00N/AEarnings ReportAnalyst RevisionAVNSAVANOS MEDICAL1.6246 of 5 stars$11.28+2.7%N/A-52.2%$507.76M$687.80M-1.352,227Earnings ReportAnalyst Downgrade Related Companies and Tools Related Companies IRMD Alternatives KMTS Alternatives SIBN Alternatives BBNX Alternatives EMBC Alternatives AXGN Alternatives ZIMV Alternatives BVS Alternatives CBLL Alternatives AVNS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BWAY) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainsway Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainsway With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale